Revlimid (lenalidomide) generics launch across Europe

Generics/News | Posted 01/04/2022 post-comment0 Post your comment

In late February 2022, a number of generics of Revlimid (lenalidomide) were launched in Europe. These will now rival Bristol Meyers Squibb’s blockbuster oncology medicine.

Cancer Cell V13I20

Amongst those who have launched lenalidomide generics are Novartis’ generics unit, Sandoz, who announced the launch of a generic version of Revlimid (lenalidomide) in 19 countries in Europe. German generics maker Stada Arzneimittel has also launched in some European countries and the UK’s Accord Healthcare is launching a generic version of the drug in Europe and the UK.

Lenalidomide is an oncology drug product for the treatment of adult patients with multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma and follicular lymphoma. Revlimid was first launched in Europe in 2006 by Celgene that was subsequently acquired by Bristol Meyers Squibb. Revlimid is a blockbuster drug, generating US$12.8 billion for Bristol Meyers Squibb in 2021.

Generic versions of Revlimid have also already launched in Canada and are set to be launched on the US market in March 2022. Dr Reddy’s Laboratories’ lenalidomide generic was approved in the US in October 2021 and their 2.5 mg and 20 mg strength capsules are eligible for 180 days of generic drug exclusivity [1].

Related articles
EMA recommends approval of Lenalidomide Mylan

Generics applications under review by EMA – July 2020


The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View last week’s headline article: Nomenclatura de biológicos y biocomparables en México

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.


Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Vea el artículo principal de la semana pasada: Nomenclatura de biológicos y biocomparables en México

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 


1. GaBI Online - Generics and Biosimilars Initiative. Sun Pharma and Dr Reddy’s generics progress in EU and US []. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Apr 1]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2022 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010